These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 24105670)

  • 1. Developing biomarkers to predict benefit from HGF/MET pathway inhibitors.
    Koeppen H; Rost S; Yauch RL
    J Pathol; 2014 Jan; 232(2):210-8. PubMed ID: 24105670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The emerging role of MET/HGF inhibitors in oncology.
    Scagliotti GV; Novello S; von Pawel J
    Cancer Treat Rev; 2013 Nov; 39(7):793-801. PubMed ID: 23453860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
    Eder JP; Vande Woude GF; Boerner SA; LoRusso PM
    Clin Cancer Res; 2009 Apr; 15(7):2207-14. PubMed ID: 19318488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the hepatocyte growth factor/Met pathway in cancer.
    De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
    Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges.
    Liu X; Newton RC; Scherle PA
    Trends Mol Med; 2010 Jan; 16(1):37-45. PubMed ID: 20031486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives.
    Bahrami A; Shahidsales S; Khazaei M; Ghayour-Mobarhan M; Maftouh M; Hassanian SM; Avan A
    J Cell Physiol; 2017 Oct; 232(10):2657-2673. PubMed ID: 28075018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in cancer therapy targeting c-Met signaling pathway.
    Jung KH; Park BH; Hong SS
    Arch Pharm Res; 2012 Mar; 35(4):595-604. PubMed ID: 22553051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. c-Met targeting in advanced gastric cancer: An open challenge.
    Marano L; Chiari R; Fabozzi A; De Vita F; Boccardi V; Roviello G; Petrioli R; Marrelli D; Roviello F; Patriti A
    Cancer Lett; 2015 Aug; 365(1):30-6. PubMed ID: 26049023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug development of MET inhibitors: targeting oncogene addiction and expedience.
    Comoglio PM; Giordano S; Trusolino L
    Nat Rev Drug Discov; 2008 Jun; 7(6):504-16. PubMed ID: 18511928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-MET kinase inhibitors: a patent review (2011 - 2013).
    Zhu K; Kong X; Zhao D; Liang Z; Luo C
    Expert Opin Ther Pat; 2014 Feb; 24(2):217-30. PubMed ID: 24266843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress.
    Cui JJ
    J Med Chem; 2014 Jun; 57(11):4427-53. PubMed ID: 24320965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting c-MET/HGF signaling pathway in upper gastrointestinal cancers: rationale and progress.
    Gholamin S; Fiuji H; Maftouh M; Mirhafez R; Shandiz FH; Avan A
    Curr Drug Targets; 2014; 15(14):1302-11. PubMed ID: 25382190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small molecule c-Met kinase inhibitors: a review of recent patents.
    Porter J
    Expert Opin Ther Pat; 2010 Feb; 20(2):159-77. PubMed ID: 20100000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors.
    Bode CM; Boezio AA; Albrecht BK; Bellon SF; Berry L; Broome MA; Choquette D; Dussault I; Lewis RT; Lin MH; Rex K; Whittington DA; Yang Y; Harmange JC
    Bioorg Med Chem Lett; 2012 Jun; 22(12):4089-93. PubMed ID: 22595176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of c-MET pathway inhibitors.
    Liu X; Newton RC; Scherle PA
    Expert Opin Investig Drugs; 2011 Sep; 20(9):1225-41. PubMed ID: 21740293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarker development in MET-targeted therapy.
    Zhang Y; Du Z; Zhang M
    Oncotarget; 2016 Jun; 7(24):37370-37389. PubMed ID: 27013592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?
    Gaule PB; Crown J; O'Donovan N; Duffy MJ
    Expert Opin Ther Targets; 2014 Sep; 18(9):999-1009. PubMed ID: 25084805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma.
    Finisguerra V; Prenen H; Mazzone M
    Oncogene; 2016 Oct; 35(42):5457-5467. PubMed ID: 26996670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in the discovery of small molecule c-Met Kinase inhibitors.
    Parikh PK; Ghate MD
    Eur J Med Chem; 2018 Jan; 143():1103-1138. PubMed ID: 29157685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
    Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
    Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.